King's Research Portal

DOI:

[10.1002/hep.30059](https://doi.org/10.1002/hep.30059)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Lim, T. Y., Martinez-Llordella, M., Kodela, E., Gray, E., Heneghan, M. A., & Sanchez-Fueyo, A. (2018). Low Dose Interleukin-2 for Refractory Autoimmune Hepatitis. *Hepatology*, 68(4), 1649-1652.
<https://doi.org/10.1002/hep.30059>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Low Dose Interleukin-2 for Refractory Autoimmune Hepatitis

Tiong Y. Lim¹ , Marc Martinez-Llordella¹, Elisavet Kodela¹, Elisabeth Gray¹,
Michael A. Heneghan^{1*}, and Alberto Sanchez-Fueyo^{1*}

¹Institute of Liver Studies, King's College Hospital, Medical Research Council (MRC) Centre for Transplantation, School of Immunology & Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Denmark Hill, London, SE5 9RS, United Kingdom.

* Both authors contributed equally to this work.

Corresponding Author:

Professor Alberto Sanchez-Fueyo, Liver Sciences Section, James Black Centre, King's College London, Denmark Hill, London SE5 9NU, United Kingdom.

Tel: +44 (0) 20 3299 4015

Fax: +44 (0) 20 3299 3167

E-mail: sanchez_fueyo@kcl.ac.uk

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hep.30059

Abbreviations:

AIH	– Autoimmune Hepatitis
ANA	– Anti-neutrophil Antibody
AST	– Aspartate Aminotransferase
CXCL10	– C-X-C Motif Chemokine Ligand 10
FOXP3	– Forkhead-box-P3
IgG	– Immunoglobulin G
IL-2	– Interleukin-2
IL-10	– Interleukin-10
IP-10	– Interferon-Inducible Protein-10
IQR	– Interquartile Range
LDIL-2	– Low Dose Interleukin-2
MFI	– Mean Fluorescence Intensity
MMF	– Mycophenolate Mofetil
pSTAT5	– Phosphorylated Signal Transducer and Activator of Transcription-5
SEM	– Standard Error of Mean
SLA	– Anti-Soluble Liver Antigen
SMA	– Anti-Smooth Muscle Antibody
Tcon	– CD4 ⁺ CD25 ⁺ FoxP3 ⁺ T Conventional Cell
Treg	– CD4 ⁺ CD25 ⁺ Fopx3 ⁺ T Regulatory Cell

Keywords: Autoimmune hepatitis; interleukin-2; regulatory T-cells

Conflicts of Interest: The authors who have taken part in this study declare that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Grants & Financial Support: This work was funded by King's Health Partners Research Grant R140807 (to M.M.-L.) and Medical Research Council Grant MR/L008890/1 (to A.S.-F.). We thank all the subjects and patients who volunteered for this study and the Medical Research Council Centre for Transplantation (reference J006742/1) and the National Institute for Health Research Biomedical Research Centre based at Guy's and St Thomas' National Health Service Foundation Trust and King's College London. MAH is supported by generous donations from the Kelly Group, King's College Hospital Charity, EASL Registry Grant and the Sidney Orpin Bequest.

INTRODUCTION

The management of autoimmune hepatitis (AIH) has largely remained unchanged for the past three decades. The optimal regimen for patients who do not respond to first-line treatment of corticosteroids with-or-without azathioprine remains unclear. There is growing interest in the use of immunotherapies targeting CD4⁺Forkhead-box-P3(Foxp3)⁺ regulatory T-cells (Tregs). Tregs are a T-lymphocyte sub-population with immunosuppressive and cytoprotective capacity that play a key role in restraining auto-reactive conventional T-lymphocytes (Tcons) and preventing autoimmunity. Due to their constitutive expression of CD25, the alpha-chain of the interleukin-2-receptor, Tregs are highly dependent on, and exquisitely sensitive to, IL-2.(1) The use of low-dose IL-2 (LDIL-2) as an immunomodulatory agent is being explored in various autoimmune disorders.(2) We report here the clinical and immunological effects of LDIL-2 in two patients with refractory AIH.

Patients

Patient-1 had previously required repeated intravenous corticosteroid courses for AIH flares despite triple therapy. Patient-2 was intolerant to azathioprine, had suffered multiple flares whilst on MMF and prednisolone, and refused initiating Tacrolimus due to long-term toxicity concerns. Both patients had persistent disease activity as assessed by serum biochemistry and a liver biopsy performed within the previous 12months (Table_1). IL-2 (Proleukin, Novartis Pharmaceuticals UK) was administered as 1million IU subcutaneous injections for 5 consecutive days monthly, for 6months. Patients gave written informed consent to receive LDIL-2 under a clinical protocol approved by King's Medicines

Management Committee, and to participate in an immunomonitoring study (REC15/NS/0062) involving collection of sequential peripheral blood samples.

Patient-1 experienced no significant changes in aspartate aminotransferase (AST) and immunoglobulin-G (IgG) levels between baseline and end-of-treatment. Conversely, in patient-2 both AST and IgG levels decreased to within the normal range by end-of-treatment (Table_1 and Fig.1A). No adverse events other than rapidly resolving mild injection-site reactions were observed.

The proportion of circulating Tregs increased significantly in both patients by day-4 after each cycle of LDIL-2, peaking at day-9, and returned to baseline values at day-28 (Fig.1B). The changes in Tregs were due to increases in the proportion of resting (CD45RA⁺FOXP3^{lo}) and effector Tregs (CD45RA⁺FOXP3^{hi}), with no significant changes in the cytokine-secreting, non-suppressive CD45RA⁺FOXP3^{lo} subset (Sup_Fig.1A-B). LDIL-2 therapy also resulted in increases in soluble CD25, Treg proliferation (as assessed by Ki-67), and in the Treg expression of CD25 and FOXP3 (considered surrogate markers of suppressive capacity) (Sup_Figs.1C-E, 3B & 5F-G). We measured intra-cellular pSTAT5 to assess the IL-2 Treg sensitivity. At baseline, Tregs from both patients exhibited lower pSTAT5 levels than those from age-matched healthy controls, but this was normalized following LDIL-2 therapy (Fig.1D).

DISCUSSION

We provide here what to the best of our knowledge is the first evidence suggesting that administration of LDIL-2 to AIH patients is safe and effective in increasing the pool of circulating Tregs. While we observed a consistent increase in Tregs following LDIL-2 therapy, this effect was of shorter duration and lower

magnitude than that reported in patients receiving higher and/or more frequent doses (1-3millionIU/day),(2) suggesting these alternative regimens might be preferable to sustain the expanded Treg pool. Of note, LDIL-2 treatment increased the IL-2 sensitivity of Tregs and corrected the suboptimal pSTAT5 response recently described as being a hallmark of AIH.(3) Importantly, the effects of LDIL-2 were restricted to Tregs, as we detected no significant changes in non-Treg immune cell subsets (Fig.1C and Supplementary Results). Animal data indicate that intra-hepatic Treg expansion is compromised in the presence of severe liver damage.(4) This could account for patient-1 lack of clinical response.

In conclusion, our observations demonstrate the feasibility of using LDIL-2 to improve inflammatory liver damage by increasing the pool of immunoregulatory lymphocytes. Our data provide rationale and a proof-of-principle to further explore the clinical use of LDIL-2 in the management of autoimmune liver diseases.

REFERENCES

1. Matsuoka K-i, Koreth J, Kim HT, Bascug OG, McDonough S, Kawano Y, Murase K, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. *Sci Transl Med* 2013;5.
2. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol* 2013;1:295-305.
3. Liberal R, Grant CR, Holder BS, Cardone J, Martinez-Llordella M, Ma Y, Heneghan MA, et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. *Hepatology* 2015;62:863-875.
4. Heymann F, Peusquens J, Ludwig-Portugall I, Kohlhepp M, Ergen C, Niemietz P, Martin C, et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. *Hepatology* 2015;62:279-291.

Table 1. Clinical characteristics of the 2 patients receiving low-dose interleukin-2 (LDIL-2) treatment. Baseline serum tests were taken prior to initiating LDIL-2 treatment, whilst end of treatment was taken at 3 months following completion of last (sixth) cycle of LDIL-2 treatment.

Patient Characteristics	Patient-1	Patient-2
Age (years)	20	56
Sex	Female	Female
Age at diagnosis (years)	13	51
Duration of disease (years)	7	5
Serology	SMA+ (1/160)	ANA+ (1/40) Anti-SLA +
IAIHG Score	8	9
Immunosuppression at baseline	Tacrolimus 1mg OD MMF 1g BD Prednisolone 15mg OD	MMF 1g BD Prednisolone 15mg OD
Liver histology	Severe autoimmune hepatitis with cirrhosis	Moderate chronic hepatitis with interface activity and focal bridging fibrosis
Baseline serum tests (normal range)		
• AST (10-50 IU/ml)	149	259
• Globulin (25-35 g/l)	53	43
• Immunoglobulin G (6.3-18.1 g/l)	29.4	20.9
• Albumin (35-50 g/l)	42	44
• Bilirubin (3-20 μ mol/l)	40	14
• Platelet (150-450 $\times 10^9$ /l)	152	198
• INR (0.90-1.20)	1.17	1.11
Serum tests at end-of-treatment		
• AST (10-50 IU/ml)	174	44
• Globulin (25-35 g/l)	49	33
• Immunoglobulin G (6.3-18.1 g/l)	30.2	16.2
• Albumin (35-50 g/l)	37	41
• Bilirubin (3-20 μ mol/l)	33	55
• Platelet (150-450 $\times 10^9$ /l)	132	191
• INR (0.90-1.20)	1.07	1.06

*SMA – smooth muscle antibodies, ANA – anti-neutrophil antibody, Anti-SLA – anti-soluble liver antigen, MMF – Mycophenolate mofetil, AST – aspartate aminotransferase, OD – Once Daily, BD – bis die/twice daily, INR – International Normalised Ratio.

Fig. 1. Effect of low-dose interleukin-2 (LDIL-2) 5-day treatment cycles, (depicted in grey shade) on serum biochemistry and circulating CD4⁺CD25⁺FoxP3⁺ regulatory T-cells (Tregs). (A) Sequential changes in serum AST levels during the 6 cycles of LDIL-2 treatment for each patient. **(B)** Proportion of Tregs before and after each of the cycles of LDIL-2 treatment.. **(C)** Changes in the proportion of Tregs, conventional T-cells (Tcons) and natural killer (NK) cells after combining the data from the 12 cycles of LDIL-2 treatment from both patients (data show mean and standard error of mean, SEM, * = p-value <0.05, ** = p-value <0.005). **(D)** Sensitivity to IL-2 of circulating Tregs collected before and at different time points after initiating LDIL-2. The response to IL-2 was assessed by measuring in Tregs the mean fluorescence intensity of intracellular pSTAT5 (pSTAT5 MFI; y-axis) by flow cytometry following *ex vivo* stimulation with increasing concentrations of IL-2 (x-axis). Data shown correspond to 3 healthy controls and 2 patients and are expressed as mean $\pm$ SEM.

209x297mm (300 x 300 DPI)